{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:24:49Z","timestamp":1792689889353,"version":"4.5.0"},"reference-count":13,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OVS"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Multiple myeloma is the most common plasma cell tumor; however, ocular plasmacytomas are rare. Few cases of binocular metastasis have been reported. The authors review a case study using intraocular bevacizumab to treat secondary glaucoma and binocular metastasis from multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>A 59\u2010year\u2010old woman with a 13\u2010month history of multiple myeloma was found to have a suspected masquerade syndrome OS and subsequently developed a neovascular glaucoma within 2 months. Intravitreal bevacizumab injection OS controlled the intraocular pressure and inhibited ocular metastasis. The methods of therapy administration in this case are consistent with procedures commonly used in clinical practice when using bevacizumab to treat other etiologies, such as choroidal neovascular membranes. Lost to follow\u2010up until 2 months later, the patient presented with ocular metastasis OD with the same changes as observed OS. Conjunctival biopsy revealed subconjunctival plasmoma OD. After intravitreal bevacizumab injection, neovascular glaucoma OD was partly controlled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Secondary ocular plasmacytoma, despite its rarity, should be considered in patients with multiple myeloma. Intravitreal bevacizumab injection may be a promising treatment for ocular metastases and associated secondary or neovascular glaucoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/opx.0b013e31829caaf7","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T07:28:30Z","timestamp":1372404510000},"source":"Crossref","is-referenced-by-count":14,"title":["Intravitreal Bevacizumab for Ocular Metastasis of Multiple Myeloma"],"prefix":"10.1002","volume":"90","author":[{"given":"Qiang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Liang","sequence":"additional","affiliation":[{"name":"Beijing Chaoyang Hospital Capital Medical University Beijing China"},{"name":"Department of Ophthalmology Peking University People's Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Capital Medical University Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,1]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar F","year":"2003","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti\u2013vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang JC","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose\u2010escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30","author":"Cobleigh MA","year":"2003","journal-title":"Semin Oncol"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age\u2010related macular degeneration","volume":"364","author":"Martin DF","year":"2011","journal-title":"N Engl J Med"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment","volume":"26","author":"Avery RL","year":"2006","journal-title":"Retina"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ajo.2006.06.066","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma","volume":"142","author":"Iliev ME","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9394(14)71227-9","article-title":"Metastatic tumors to the iris in 40 patients","volume":"119","author":"Shields JA","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3928\/15428877-20120517-03","article-title":"Successful management of choroidal metastasis with intravitreal ranibizumab injections","volume":"43","author":"Detorakis ET","year":"2012","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10384-010-0892-z","article-title":"Intravitreal bevacizumab for iris metastasis of small\u2010cell lung carcinoma with neovascular glaucoma","volume":"55","author":"Nakashima C","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1001\/archophthalmol.2008.2","article-title":"Regression of a subfoveal choroidal metastasis of colorectal carcinoma after intravitreous bevacizumab treatment","volume":"126","author":"Kuo IC","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2141.2011.08623.x","article-title":"Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed\/refractory multiple myeloma: a California Cancer Consortium trial","volume":"154","author":"Somlo G","year":"2011","journal-title":"Br J Haematol"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","volume":"119","author":"White D","year":"2012","journal-title":"Cancer"},{"key":"e_1_2_6_14_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.optm.2010.10.009","article-title":"Ocular manifestations of multiple myeloma: three cases and a review of the literature","volume":"82","author":"Chin KJ","year":"2011","journal-title":"Optometry"}],"container-title":["Optometry and Vision Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/OPX.0b013e31829caaf7","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1097\/OPX.0b013e31829caaf7","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/OPX.0b013e31829caaf7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:12:59Z","timestamp":1774951979000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/OPX.0b013e31829caaf7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1097\/OPX.0b013e31829caaf7"],"URL":"https:\/\/doi.org\/10.1097\/opx.0b013e31829caaf7","archive":["Portico"],"relation":{},"ISSN":["1040-5488","1538-9235"],"issn-type":[{"value":"1040-5488","type":"print"},{"value":"1538-9235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}